Our News

Press Releases

Tolero is a leading developer of novel therapeutics to inhibit biologic drivers of oncologic and hematologic diseases. A list of recent press releases and other news from Tolero can be found below. We welcome inquiries about our pathway-centric pipeline and our novel approach to drug discovery. To contact our media relations staff, click here.

December 1, 2018

Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018

November 15, 2018

Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors

November 2, 2018

Tolero Pharmaceuticals to highlight new data evaluating investigational agents Alvocidib and TP-1287 at 2018 American Society of Hematology annual meeting

October 16, 2018

Tolero Pharmaceuticals announces first patient dosed with investigational agent Alvocidib in phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS)

August 17, 2018

Tolero Pharmaceuticals announces clinical research collaboration with AbbVie for acute myeloid leukemia trial.

July 25, 2018

Tolero Pharmaceuticals announces first patient dosed with investigational agent TP-0184, an activin A receptor type 1 (ACVR1) inhibitor, in phase 1 study of patients with advanced solid tumors

July 23, 2018

Tolero Pharmaceuticals advances investigational agent alvocidib into second stage of phase 2 Zella 201 study in patients with relapsed refractory MCL-1–dependent AML

June 15, 2018

Tolero Pharmaceuticals presents clinical data for investigational agent alvocidib in patients with relapsed refractory MCL-1—dependent AML at EHA 2018

May 18, 2018

Tolero Pharmaceuticals to present clinical data evaluating investigational agent alvocidib in patients with relapsed refractory MCL-1—dependent AML at EHA 2018

April 13, 2018

Tolero Pharmaceuticals to present preclinical data supporting apoptosis—inducing activity of alvocidib in acute myeloid leukemia

November 10, 2017

Tolero Pharmaceuticals opens new headquarters in Lehi

October 23, 2017

Tolero Pharmaceuticals announces preclinical data supporting development of TP-1287 and TP-3654 for MYC-dependent triple-negative breast cancer

October 5, 2017

Tolero Pharmaceuticals to deliver keynote presentations at the 9th International Conference on Leukemia and Hematologic Oncology

June 21, 2017

Tolero Pharmaceuticals to expand enrollment of phase II study of alvocidib in MCL-1–dependent AML into Europe

June 15, 2017

Tolero Pharmaceuticals to present supportive preclinical data for investigational CDK inhibitor alvocidib at European Hematology Association annual meeting

April 5, 2017

Tolero Pharmaceuticals presents preclinical data on CDK9 inhibitor alvocidib and its prodrug, TP-1287, at AACR 2017

January 26, 2017

Sumitomo Dainippon Pharma completes acquisition of Tolero Pharmaceuticals, Inc (US biotechnology company)

Want to know more? Read about our latest findings.